BridgeBio Oncology
BBOT
32 hedge funds and large institutions have $173M invested in BridgeBio Oncology in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
3% more funds holding
Funds holding: 31 → 32 (+1)
1% more capital invested
Capital invested by funds: $171M → $173M (+$1.58M)
0.38% more ownership
Funds ownership: 86.59% → 86.97% (+0.38%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$521K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$368K |
| 3 |
Millennium Management
New York
|
+$126K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$73.9K |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$27.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.25M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$419K |
| 3 |
BlackRock
New York
|
-$11.9K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$842 |
| 5 |
JP Morgan Chase
New York
|
-$42 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WP
26
Woodline Partners
San Francisco,
California
| $1.08M | – | – | – |
|
|
MCM
27
Moore Capital Management
New York
| $1.05M | – | – | – |
|
|
28
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $520K | +$521K | +49,500 | New |
|
|
29
UBS Group
Zurich,
Switzerland
| $367K | +$368K | +34,927 | +166,319% |
|
|
GAM
30
Gritstone Asset Management
Bethesda,
Maryland
| $259K | +$260K | +24,666 | New |
|
31
Geode Capital Management
Boston,
Massachusetts
| $139K | +$25.3K | +2,405 | +22% |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $10 | +$11 | +1 | New |
|
|
SSA
33
Schonfeld Strategic Advisors
New York
| – | -$1.25M | -119,880 | Closed |
|
|
CAC
34
Cowen and Company
New York
| – | -$471K | -45,048 | Closed |
|
|
35
JP Morgan Chase
New York
| – | -$42 | -4 | Closed |
|
BBOT Hedge Fund Activity: Q4 2024 in Review
32 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q4 2024, worth a combined $173M — up 0.92% from $171M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BBOT positions and 3 closed out — a net gain of 2 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $521K. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $1.25M sold.
- 32 institutional investors held BridgeBio Oncology (BBOT) as of Q4 2024, up from 31 in Q3 2024.
- Funds reported $173M of BridgeBio Oncology stock for Q4 2024, up 0.92% quarter-over-quarter.
- 5 funds opened new BridgeBio Oncology positions in Q4 2024 and 3 closed out, a net change of +2 holders.
- The largest BridgeBio Oncology buyer in Q4 2024 was Toronto Dominion Bank, an estimated $521K added.
- The largest BridgeBio Oncology seller in Q4 2024 was Schonfeld Strategic Advisors, an estimated $1.25M sold.
Based on aggregated 13F filings for Q4 2024.